Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1994 Mar 15;91(6):1983–1984. doi: 10.1073/pnas.91.6.1983

Pharmacogenetics: the slow, the rapid, and the ultrarapid.

U A Meyer 1
PMCID: PMC43291  PMID: 8134334

Full text

PDF
1983

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALVING A. S., CARSON P. E., FLANAGAN C. L., ICKES C. E. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956 Sep 14;124(3220):484–485. doi: 10.1126/science.124.3220.484-a. [DOI] [PubMed] [Google Scholar]
  2. Armstrong M., Daly A. K., Cholerton S., Bateman D. N., Idle J. R. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet. 1992 Apr 25;339(8800):1017–1018. doi: 10.1016/0140-6736(92)90537-d. [DOI] [PubMed] [Google Scholar]
  3. Beutler E. Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med. 1991 Jan 17;324(3):169–174. doi: 10.1056/NEJM199101173240306. [DOI] [PubMed] [Google Scholar]
  4. Blum M., Demierre A., Grant D. M., Heim M., Meyer U. A. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5237–5241. doi: 10.1073/pnas.88.12.5237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Broly F., Gaedigk A., Heim M., Eichelbaum M., Morike K., Meyer U. A. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 1991 Oct;10(8):545–558. doi: 10.1089/dna.1991.10.545. [DOI] [PubMed] [Google Scholar]
  6. Broly F., Meyer U. A. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics. 1993 Jun;3(3):123–130. [PubMed] [Google Scholar]
  7. Evans D. A. N-acetyltransferase. Pharmacol Ther. 1989;42(2):157–234. doi: 10.1016/0163-7258(89)90036-3. [DOI] [PubMed] [Google Scholar]
  8. Gaedigk A., Blum M., Gaedigk R., Eichelbaum M., Meyer U. A. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet. 1991 May;48(5):943–950. [PMC free article] [PubMed] [Google Scholar]
  9. Gonzalez F. J., Skoda R. C., Kimura S., Umeno M., Zanger U. M., Nebert D. W., Gelboin H. V., Hardwick J. P., Meyer U. A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988 Feb 4;331(6155):442–446. doi: 10.1038/331442a0. [DOI] [PubMed] [Google Scholar]
  10. Gough A. C., Smith C. A., Howell S. M., Wolf C. R., Bryant S. P., Spurr N. K. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis. Genomics. 1993 Feb;15(2):430–432. doi: 10.1006/geno.1993.1082. [DOI] [PubMed] [Google Scholar]
  11. Heim M. H., Meyer U. A. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics. 1992 Sep;14(1):49–58. doi: 10.1016/s0888-7543(05)80282-4. [DOI] [PubMed] [Google Scholar]
  12. Heim M., Meyer U. A. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet. 1990 Sep 1;336(8714):529–532. doi: 10.1016/0140-6736(90)92086-w. [DOI] [PubMed] [Google Scholar]
  13. Johansson I., Lundqvist E., Bertilsson L., Dahl M. L., Sjöqvist F., Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11825–11829. doi: 10.1073/pnas.90.24.11825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. KALOW W., GENEST K. A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine numbers. Can J Biochem Physiol. 1957 Jun;35(6):339–346. doi: 10.1139/y57-041. [DOI] [PubMed] [Google Scholar]
  15. Kagimoto M., Heim M., Kagimoto K., Zeugin T., Meyer U. A. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem. 1990 Oct 5;265(28):17209–17214. [PubMed] [Google Scholar]
  16. La Du B. N. Identification of human serum cholinesterase variants using the polymerase chain reaction amplification technique. Trends Pharmacol Sci. 1989 Aug;10(8):309–313. doi: 10.1016/0165-6147(89)90062-x. [DOI] [PubMed] [Google Scholar]
  17. MOTULSKY A. G. Drug reactions enzymes, and biochemical genetics. J Am Med Assoc. 1957 Oct 19;165(7):835–837. doi: 10.1001/jama.1957.72980250010016. [DOI] [PubMed] [Google Scholar]
  18. Mouchès C., Pasteur N., Bergé J. B., Hyrien O., Raymond M., de Saint Vincent B. R., de Silvestri M., Georghiou G. P. Amplification of an esterase gene is responsible for insecticide resistance in a California Culex mosquito. Science. 1986 Aug 15;233(4765):778–780. doi: 10.1126/science.3755546. [DOI] [PubMed] [Google Scholar]
  19. Prody C. A., Dreyfus P., Zamir R., Zakut H., Soreq H. De novo amplification within a "silent" human cholinesterase gene in a family subjected to prolonged exposure to organophosphorous insecticides. Proc Natl Acad Sci U S A. 1989 Jan;86(2):690–694. doi: 10.1073/pnas.86.2.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Schimke R. T., Sherwood S. W., Hill A. B., Johnston R. N. Overreplication and recombination of DNA in higher eukaryotes: potential consequences and biological implications. Proc Natl Acad Sci U S A. 1986 Apr;83(7):2157–2161. doi: 10.1073/pnas.83.7.2157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Skoda R. C., Gonzalez F. J., Demierre A., Meyer U. A. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5240–5243. doi: 10.1073/pnas.85.14.5240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Smith C. A., Gough A. C., Leigh P. N., Summers B. A., Harding A. E., Maraganore D. M., Sturman S. G., Schapira A. H., Williams A. C., Maranganore D. M. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet. 1992 Jun 6;339(8806):1375–1377. doi: 10.1016/0140-6736(92)91196-f. [DOI] [PubMed] [Google Scholar]
  23. Stark G. R. Regulation and mechanisms of mammalian gene amplification. Adv Cancer Res. 1993;61:87–113. doi: 10.1016/s0065-230x(08)60956-2. [DOI] [PubMed] [Google Scholar]
  24. Vesell E. S. Twin studies in pharmacogenetics. Hum Genet Suppl. 1978;(1):19–30. doi: 10.1007/978-3-642-67179-1_4. [DOI] [PubMed] [Google Scholar]
  25. Wright J. A., Smith H. S., Watt F. M., Hancock M. C., Hudson D. L., Stark G. R. DNA amplification is rare in normal human cells. Proc Natl Acad Sci U S A. 1990 Mar;87(5):1791–1795. doi: 10.1073/pnas.87.5.1791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yokota H., Tamura S., Furuya H., Kimura S., Watanabe M., Kanazawa I., Kondo I., Gonzalez F. J. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics. 1993 Oct;3(5):256–263. doi: 10.1097/00008571-199310000-00005. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES